ABSTRACT BACKGROUND: Encapsulating peritoneal sclerosis (EPS) related to peritoneal dialysis (PD) has a vague etiology and high mortality. In this study, our aim was to determine treatment options for EPS cases.
MATERIALS AND METHODS
All patients, 18 years of age and older, who underwent kidney transplantation and had previously received PD were included into this study. Patients who underwent both PD and hemodialysis before the transplantation were excluded. Demographic and clinical data were obtained from the medical documents. The age at the start of PD, gender, the cause of end-stage kidney disease, prior kidney replacement therapy, comorbid disease(s), history of abdominal surgery, PD duration, the number of peritonitis indications for surgery, results of surgery, postoperative complications, and long-term results were evaluated. The EPS diagnosis was made according to the criteria published by the International Society for PD in 2000.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) was first described back in 1980 by Gandhi et al. It is a disease related to peritoneal dialysis (PD) with a vague etiology and high mortality. EPS occurs in a minority of patients undergoing chronic PD, but it may be life-threatening. The major risk factor for EPS is the PD duration. A history of abdominal surgery and recurrent peritonitis are other important factors for the development of EPS. [1, 2] EPS usually presents with mechanical intestinal obstruction, causing nausea, vomiting, and weight loss. [3] [4] [5] EPS occurs after kidney transplantation. [6, 7] Immunosuppressive medications and tamoxifen (anti-fibrotic) are used for medical treatment. If medications fail to improve the patient's condition, surgery seems to be the best option. Surgical intervention is usually required in refractory cases, and these patients are associated with high mortality rates.
RESULTS
We retrospectively analyzed information on 169 adult patients who underwent kidney transplantation at our center between January 2008 and January 2018-119 patients from a cadaveric and 50 patients from a living donor. Twenty-one patients had received previously PD before the transplantation. The mean PD time was 6.9 (3-14) years. Four patients received surgical treatment for EPS, which occurred after the transplantation. Two of them were males, and the mean age was 41.
One patient received a cadaveric kidney transplant, and 3 received it from a living donor. All the grafts functioned well in the early period, and there were no complications during the hospitalization. PD characteristic and outcomes of the patients are shown in Table 1 . All of the patients' PD catheters were removed at kidney transplantation. After the removal of the PD catheter, 3 patients were readmitted within 1 year, and the remaining patient within 2 years, due to nausea, vomiting, early satiety, and weight loss. In one case, laparotomy, enteroclysis, segmental small intestine resection, and double barrel ileostomy were performed due to empty organ perforation (Figs. 1 and 2). We performed diagnostic laparoscopy in 1 patient with intraperitoneal liquid sampling and peritoneal biopsy (Fig. 3) . In 2 cases, laparotomy, total small intestine enterocytes, segmental small intestinal resection, and end ileostomy were performed due to full obstruction of a small intestinal segment. Two patients died because of sepsis. Two patients were discharged without complications, but 1 had late-term EPS recurrence (Fig. 4) .
DISCUSSION
EPS is a rare but serious complication encountered in patients treated with PD for a long time. Although its prevalence is variable, in Japan, where nearly all patients are managed with PD, the prevalence of EPS is reported to be 2.5%. [10] The prevalence of EPS is 0.9% in patients who have been on PD less than 5 years, but it is 11.5% in patients on PD for more than 10 years. [10] According to the Pan-Thames EPS study done in the United Kingdom, 71% of 111 patients diagnosed with EPS have been on PD for more than 5 years. [6] In our study, the mean time of PD duration before the EPS diagnosis is 10.5 (9-13) years. The changes in the peritoneal layers and "the second hit" are considered to lead to the clinical findings of EPS. [9] A long-term PD causes an increase in the mesothelial cell count due to a continuous contact with dialysate, a decrease in microvilli, and disorganized distribution of collagen bundles. [11] The mesothelial basement membrane, peritoneal interstitial area, and capillary basement membrane are all thickened. [11] In our study, we saw an abundance of blood elements, mesothelial cells, and wide fibrosis in the pathologic specimens. This sclerosis and fibrosis cause a peritonitis attack leading to a second hit, and after the removal of the PD catheter, encapsulation occurs. [9] In our cases, EPS occurred at the latest 2 years after the removal of the PD catheter. Because of this, the PD catheter removal after the transplant is blamed for the second hit.
The EPS diagnosis is made according to the criteria published by the International Society for Peritoneal Dialysis in 2000. [12] The EPS diagnosis is based on clinical findings of a systemic inflammatory reaction because an obstructive ileus state must be detected, and thickening of the peritoneum, encapsulation, calcification, and obstruction should be seen on abdominal computed tomography (CT). According to recent studies, abdominal CT is the main imaging modality, and it was also the main diagnostic tool in our studies. The intra-abdominal localized liquid collection, thickening of the peritoneum, and imaging related to ileus were seen in all our patients; additional peritoneal calcifications were encountered in some.
Nearly all EPS cases occur after the PD treatment ends. [10] In the study published in 2009, Brown et al. presented a large series of the EPS cases. Between 2000 and 2007, a total of 1238 patients were treated with PD, and 46 (3.7%) of them were diagnosed with EPS. Twelve patients were diagnosed while on PD, 29 patients were diagnosed after ending PD, and 1 patient 1 year after the treatment had ended. In our study, 3 patients were diagnosed with EPS in the 1st year and 1 patient in the 2 nd year.
Patients diagnosed with EPS are provided with enteral nutrition support if oral intake is inadequate, and there is a significant weight loss observed. If the patient does not tolerate the enteral support, parenteral nutrition can be considered. Additional anti-inflammatory and anti-fibrotic drugs can be used if necessary. If there is no response to medical therapy, a surgical intervention is the next step. According to a report published in Japan, out of 1958 patients treated with PD, 48 presented with EPS. While 38.5% of the cases were treated with corticosteroids, 58.3% were treated surgically. [13] Medical treatment options for EPS are corticosteroids followed by immunosuppressive drugs such as azathioprine, sirolimus, and tacrolimus, and anti-fibrotic drugs such as tamoxifen. The timing of surgical intervention if medical treatment fails is critical. Surgical treatment must be sought before the condition of the patient deteriorates. [9] Laparotomy, total small intestine enteroclysis, segmental small intestinal resection, and end ileostomy due to a full obstruction of a small intestinal segment were performed in 2 cases. One patient died due to sepsis complications in the early postoperative period. In one case, laparotomy, enteroclysis, segmental small intestine resection, and double-barreled ileostomy were performed due to empty organ perforation. The patient did not have any recurrence in the follow-up period. One patient had an incomplete obstruction, so no surgical intervention was required. In 1 case, we needed to perform diagnostic laparoscopy, intra-abdominal liquid sampling, and peritoneal biopsy. This patient died due to septic complications in the early postoperative period. The mortality rate was 50% in our small patient sample.
In conclusion, EPS is a rare but serious complication of longterm PD. It has a high mortality and morbidity rate. The ending of PD treatment in long-term dialysis patients after a kidney transplant seems to be the most significant factor triggering EPS. Nutritional support and surgical intervention is the next step if the medical treatment fails. Resistant cases should be treated surgically without much delay before the condition deteriorates. It can be especially devastating for patients with a long-term PD history to have EPS after a successful transplant. Because EPS is a challenging condition, its management should be done in experienced clinics to decrease its mortality and morbidity rates.
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